Compare Garmin Ltd. (GRMN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs GeneDx Holdings Corp — how do they compare? Garmin Ltd. trades at $268.51 (market cap $51.77B), while GeneDx Holdings Corp trades at $67.59 (market cap $2.02B). The key difference: Garmin Ltd. is far larger — about 25.6× GeneDx Holdings Corp's market cap, and Garmin Ltd. pays a 1.56% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and GeneDx Holdings Corp for 19 Days on average.
| GRMN | WGS | |
|---|---|---|
Market Cap | $51.77B | $2.02B |
Volume | 961,398 | 734,640 |
Sector | Technology | Health |
52-Week High | $313.16 | $167.51 |
52-Week Low | $187.10 | $34.51 |
Typical Hold Time | 83 Days | 19 Days |
Enterprise Value | $49.28B | $2.05B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.16, down 1.09% on the day, with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $4.9B in 2022 to $7.25B in 2025, and robust profitability margins. Recent news highlights product innovation and industry awards, reinforcing its market position.
The outlook is supported by solid financial health and analyst consensus pointing to upside, but risks include competitive pressures and market volatility. The stock presents a growth opportunity driven by execution, though investor caution is warranted near-term given technical weakness and macroeconomic uncertainties.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
